Board of Governors of the Federal Reserve System, June 17, 1981.

D. Michael Manies,

Assistant Secretary of the Board.

[FR Doc. 81-18529 Filed 6-22-81; 8:45am]

BILLING CODE 6210-01-M

Northwest Funding, Inc.; Formation of Bank Holding Co.

June 17, 1981

Northwest Funding, Inc., Rockford, Illinois, has applied for the Board's approval under Section 3(a)(1) of the Bank Holding Company Act (12 U.S.C. 1842(a)(1)) to become a bank holding company by acquiring 100 percent of the voting shares of Northwest Bank of Rockford, Rockford, Illinois. The factors that are considered in acting on the application are set forth in section 3(c) of the Act (12 U.S.C. 1842(c)).

The application may be inspected at the offices of the Board of Governors or at the Federal Reserve Bank of Chicago. Any person wishing to comment on the application should submit views in writing to the reserve Bank, to be received not later than July 16, 1981. Any comment on an application that requests a hearing must include a statement of why a written presentation would not suffice in lieu of a hearing, identifying specifically any questions of fact that are in dispute and summarizing the evidence that would be presented at a hearing.

Board of Governors of the Federal Reserve System, June 17, 1981.

D. Michael Manies,

Assistant Secretary of the Board.

[FR Doc. 81-18530 Filed 6-22-81; 8:45am]

BILLING CODE 6210-01-M

SBT Bancorp, Inc.; Formation of Bank Holding Co.

SBT Bancorp, Inc., Mt. Carmel, Illinois, has applied for the Board's approval under section 3(a)(1) of the Bank Holding Company Act (12 U.S.C. 1842(a)(1)) to become a bank holding company by acquiring 100 percent of the voting shares of Security Bank and Trust Co., Mt. Carmel, Illinois. The factors that are considered in acting on the application are set forth in section 3(c) of the Act (12 U.S.C. 1842(c)).

The application may be inspected at the offices of the Board of Governors or at the Federal Reserve Bank of St. Louis. Any person wishing to comment on the application should submit views in writing to the Reserve Bank, to be received not later than July 16, 1981. Any comment on an application that requests a hearing must include a statement of why a written presentation would not suffice in lieu of a hearing, identifying specifically any questions of fact that are in dispute and summarizing the evidence that would be presented at a hearing.

Board of Governors of the Federal Reserve System, June 17, 1981.

D. Michael Maines,

Assistant Secretary of the Board.

[FR Doc. 81-18531 Filed 6-22-81; 8:45 am]

BILLING CODE 6210-01-M

Texplaza Bancshares, Inc.; Formation of Bank Holding Co.

Texplaza Bancshares, Inc., Lubbock, Texas, has applied for the Board's approval under section 3(a)(1)) of the Bank Holding Company Act (12 U.S.C. 1842 (a)(1)) to become a bank holding company by acquiring 80 percent or more of the voting shares of Texas Bank and Trust Company, Lubbock, Texas. The factors that are considered in acting on the application are set forth in section 3(c) of the Act (12 U.S.C. 1842(c)).

The application may be inspected at the offices of the Board of Governors or at the Federal Reserve Bank of Dallas. Any person wishing to comment on the application should submit views in writing to the Reserve Bank, to be received not later than July 16, 1981. Any comment on an application that requests a hearing must include a statement of why a written presentation would not suffice in lieu of a hearing, identifying specifically any questions of fact that are in dispute and summarizing the evidence that would be presented at a hearing.

Board of Governors of the Federal Reserve System, June 17, 1981.

D. Michael Maines,

Assistant Secretary of the Board.

[FR Doc. 81-18532 Filed 6-22-81; 8:45 am]

BILLING CODE 6210-01-M

FEDERAL TRADE COMMISSION

Early Termination of the Waiting Period of the Premerger Notification Rules; Timothy Mellon

AGENCY: Federal Trade Commission.

ACTION: Granting of request for early termination of the waiting period of the premerger notification rules.

SUMMARY: Timothy Mellon is granted early termination of the waiting period provided by law and the premerger notification rules with respect to the proposed acquisition of all voting securities of Maine Central Railroad Co. The grant was made by the Federal Trade Commission and the Assistant Attorney General in charge of the Antitrust Division of the Department of Justice in response to a request for early termination submitted by Timothy Mellon. Neither agency intends to take any action with respect to this acquisition during the waiting period.

EFFECTIVE DATE: June 12, 1981.

FOR FURTHER INFORMATION CONTACT: Roberta Baruch, Senior Attorney, Premerger Notification Office, Bureau of Competition, Room 303, Federal Trade Commission, Washington, D.C. 20580 (202) 523-3894.

SUPPLEMENTARY INFORMATION: Section 7A of the Clayton Act, 15 U.S.C. 18a, as added by Title II of the Hart-Scott-Rodino Antitrust Improvements Act of 1976, requires persons contemplating certain mergers or acquisitions to give the Commission and Assistant Attorney General advance notice and to wait designated periods before consummation of such plans. Section 7A(b)(2) of the Act permits the agencies, in individual cases, to terminate this waiting period prior to its expiration and requires that notice of this action be published in the **Federal Register.**

By direction of the Commission.

Carol M. Thomas,

Secretary.

[FR Doc. 81-18549 filed 6-22-81; 8:45 am]

BILLING CODE 6750-01-M

Early Termination of the Waiting Period of the Premerger Notification Rules; Marriott Corp.

AGENCY: Federal Trade Commission.

ACTION: Granting of request for early termination of the waiting period of the premerger notification rules.

SUMMARY: Marriott Corporation is granted early termination of the waiting period provided by law and the premerger notification rules with respect to the proposed acquisition of certain assets of Del E. Webb Corporation. The grant was made by the Federal Trade Commission and the Assistant Attorney General in charge of the Antitrust Division of the Department of Justice in response to a request for early termination submitted by Marriott. Neither agency intends to take any action with respect to this acquisition during the waiting period.

EFFECTIVE DATE: June 12, 1981.

FOR FURTHER INFORMATION CONTACT: Roberta Baruch, Senior Attorney, Premerger Notification Office, Bureau of Competition, Room 303, Federal Trade

Commission, Washington, D.C. 20580 (202) 523–3894.

SUPPLEMENTARY INFORMATION: Section 7A of the Clayton Act, 15 U.S.C. 18a, as added by Title II of the Hart-Scott-Rodino Antitrust Improvements Act of 1976, requires persons contemplating certain mergers or acquisitions to give the Commission and Assistant Attorney General advance notice and to wait designated periods before consummation of such plans. Section 7A(b)(2) of the Act permits the agencies, in individual cases, to terminate this waiting period prior to its expiration and requires that notice of this action be published in the Federal Register

By direction of the Commission.

Carol M. Thomas,

Secretary.

[FR Doc. 81–18550 Filed 6–22–81; 8:45 am]

BILLING CODE 6750–01–M

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

Norwich-Eaton Pharmaceuticals, Inc.; Furacin Suppositories; Withdrawal of Approval of NADA

AGENCY: Food and Drug Administration.

ACTION: Notice.

SUMMARY: The Food and Drug Administration withdraws approval of a new animal drug application (NADA) sponsored by Norwich-Eaton Pharmaceuticals, Inc., providing for use in large animals of Furacin (nitrofurazone) Suppositories as an aid in the prevention or treatment of female reproductive tract infections caused by organisms sensitive to Furacin. Norwich-Eaton Pharmaceuticals has requested the withdrawal of approval.

EFFECTIVE DATE: On or before July 6, 1981.

FOR FURTHER INFORMATION CONTACT: Mohammad I. Sharar, Bureau of Veterinary Medicine (HFV–214), Food and Drug Administration, 5600 Fishers Lane, Rockville, MD 20857, 301–443–3183.

SUPPLEMENTARY INFORMATION: Norwich-Eaton Pharmaceuticals, Division of Morton-Norwich Products, Inc., P.O. Box 191, Norwich, NY 13815, is the sponsor of NADA 8–129 which provides for use in large animals of Furacin (nitrofurazone) Suppositories as an aid in the prevention or treatment of female reproductive tract infections caused by organisms sensitive to Furacin. The application originally became effective July 20, 1951. By letter of March 23, 1981, the sponsor requested withdrawal of approval of the NADA because the product is no longer being manufactured or marketed. Section 514.115(d) of the animal drug regulations (21 CFR 514.115(d)) normally does not apply if the holder of the application whose withdrawal has been requested already has been afforded an opportunity for hearing on a proposal to withdraw the subject drug (41 FR 34899; August 17, 1976). In this case, however, Norwich's request is being granted because of the extended time interval which has elapsed since the notice of opportunity for hearing concerning NADA 8–129 was published. The Director of the Bureau of Veterinary Medicine has determined that the public interest will be served and that the sponsor's interests will not be prejudiced by the withdrawal.

Therefore, under the Federal Food, Drug, and Cosmetic Act (sec. 512(e), 82 Stat. 345–347 (21 U.S.C. 360b(e))) and under authority delegated to the Commissioner of Food and Drugs (21 CFR 5.10 (formerly 21 CFR 5.1, see 46 FR 26052; May 11, 1981)) and redelegated to the Director of the Bureau of Veterinary Medicine (21 CFR 5.84), and in accordance with section 514.115, *Withdrawal of approval of applications* (21 CFR 514.115), notice is given that approval of NADA 8–129 and all supplements for Norwich-Eaton Pharmaceuticals' Furacin (nitrofurazone) Suppositories is hereby withdrawn, effective on or before July 6, 1981.

Dated: June 16, 1981.

Gerald B. Guest,

Acting Director, Bureau of Veterinary Medicine.

[FR Doc. 81–18489 filed 6–22–81; 8:45 am]

BILLING CODE 4110–03–M

Radiological Health and Safety Advisory Committee; Request for Nominations of Voting Members

Correction

In FR Doc. 81–15002, appearing at page 28012 in the issue for Friday, May 22, 1981, please make the following correction:

On page 28012, in the first column, in the "Summary" paragraph, in the fifth line, insert the word "Standards" between the words "Safety" and "Committee".

BILLING CODE 1505–01–M

Advisory Committees; Meetings

Correction

In FR Doc. 81–17567 appearing on page 31517 in the issue of Tuesday, June 16, 1981; on page 31518, first column, insert the following heading below the second line of the paragraph designated *"Applications for reimbursement."*:

"OPHTHALMIC DEVICE SECTION OF THE OPHTHALMIC EAR, NOSE, AND THROAT; AND DENTAL DEVICES PANEL"

BILLING CODE 1505–01–M

Office of Human Development Services

Privacy Act of 1974; Report of New System of Records

AGENCY: Office of Human Development Services (HDS), DHHS.

ACTION: Notification of new system of records.

SUMMARY: In accordance with 5 U.S.C. 522a(e)(4), we are issuing public notice of our intent to consolidate several systems of records into a new umbrella system of records: HDS Publication Distribution Mailing List, HHS/HDS/OPA, 09–80–0020. We are proposing also to include routine uses with the system in accordance with 5 U.S.C. 552a(e)(11). The proposed new system of records will consolidate all of the HDS mailing lists under one uniform system to permit annual updating of the information and greater accuracy and efficiency in the distribution of the HDS public information materials. We invite public comments on the routine uses of this system of records on or before July 23, 1981.

DATES: We filed a report of new system of records with the President of the Senate, the Speaker of the House of Representatives, and the Director, Office of Management and Budget (OMB) on June 16, 1981. The system will become effective on August 17, 1981. The routine uses will become effective August 17, 1981, unless HDS receives comments which would result in a contrary determination.

ADDRESS: Address comments to the HDS Privacy Act Officer, Department of Health and Human Services, 736E Humphrey Bldg., 200 Independence Avenue, S.W., Washington, D.C. 20201. We will make comments received available for public inspection in room 734D.2 Humphrey Bldg. at the above address.

FOR FURTHER INFORMATION CONTACT: Director, Division of Publications and Graphic Services, Office of Public Affairs, 329D Humphrey Bldg., 200 Independence Avenue, S.W., Washington, D.C. 20201, (202) 472–7257.